Compare Novartis AG (NVS) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Total World Stock Index Fund ETF — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Vanguard Total World Stock Index Fund ETF trades at $161.01. The key difference: Novartis AG pays a 3.02% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VT | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $161.30 |
52-Week Low | $118.55 | $131.46 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Vanguard Total World Stock ETF (VT) trades at $161.3, up 0.86% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad global diversification across over 10,000 stocks with a low 0.06% expense ratio. Recent institutional activity shows mixed positioning adjustments, while news highlights its role in global portfolios amid trade policy uncertainty.
VT presents a long-term diversification opportunity with low-cost global equity exposure, though near-term risks include trade war volatility and seasonal choppiness. The neutral oscillator signals and high short-term RSI suggest potential consolidation, but strong institutional interest supports its core holding appeal for risk-conscious investors seeking worldwide market access.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
